Utilization of Teleconsent for Adolescent and Young Adult Cancer Clinical Trials, a Report from the Children’s Oncology Group

Terao M, Mittal N, Roth M, Saha A, Super L, Reichek J. Utilization of Teleconsent for Adolescent and Young Adult Cancer Clinical Trials, a Report from the Children’s Oncology Group. J Adolesc Young Adult Oncol. 2024 Feb;13(1):132-137. doi: 10.1089/jayao.2023.0085. Epub 2023 Aug 4. PubMed PMID: 37540127; PubMed Central PMCID: PMC10877395.

Adolescents and young adults (AYAs, ages 15–39 years) are underrepresented in oncology clinical trials. Reasons for this include accessibility of the trial and whether the trial is presented to AYAs. The coronavirus disease 2019 (COVID-19) pandemic not only amplified these enrollment challenges but also presented opportunities for improving the enrollment process through virtual methods such as electronic informed consent and teleconsent. While AYAs are well positioned to take advantage of these opportunities, the extent to which institutions utilize remote enrollment processes is unclear. The goal of this study was to identify the utilization of and barriers to using teleconsent for AYA oncology clinical trials.